Biocytogen and Sihuan partner to advance new therapeutics for weight loss
I'm LongbridgeAI, I can summarize articles.Biocytogen has partnered with Sihuan Pharmaceutical to develop new therapeutics, focusing on weight loss and other disease areas. The collaboration combines Biocytogen's human antibody discovery platform with Sihuan's drug development and commercialization expertise. This strategic alliance aims to accelerate the clinical and commercial progression of promising antibody therapeutics, leveraging advanced technologies and integrated platforms. Biocytogen's CEO, Dr. Yuelei Shen, expressed enthusiasm for the partnership, highlighting its potential to enhance their joint efforts in drug discovery and development.
Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss.
Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation.
Go deeper with GlobalData
ReportsLOA and PTSR Model - BI-907828 in Dedifferentiated Liposarcoma
- Reports
LOA and PTSR Model - BI-907828 in Lung Adenocarcinoma
Go deeper with GlobalData
The gold standard of business intelligence.
Find out more
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
The collaboration will focus on advanced therapies in multiple disease areas, including weight loss, using the companies’ complementary capabilities to support development and potential market progress.
Biocytogen will utilise its integrated platforms, including in vivo efficacy systems, target-humanised mouse models, and an AI-based antibody discovery platform developed from real human antibody sequences.
This approach is intended to support the development of new antibody therapeutics and accelerate promising molecules towards clinical and commercial stages.
Biocytogen president and CEO Dr Yuelei Shen said: “We are pleased to establish this strategic partnership with Sihuan Pharmaceutical.
“This collaboration will further expand our joint efforts across diverse disease areas and further demonstrate strong industry recognition of our technology platforms.”
Biocytogen is focused on the research and development of antibody-based drugs using gene editing technology.
The company has established a dual-engine platform that combines a fully human antibody library with a target-humanised mouse model portfolio to support global drug discovery and development.
Through its RenSuper Biologics sub-brand, it also offers an off-the-shelf library of more than a million fully human antibody sequences against over 1,000 targets.
In January 2024, Biocytogen and Radiance Biopharma signed an exclusive option and licence agreement for a bispecific antibody-drug conjugate (BsADC).